Study of a cell therapy for advanced kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new cell therapy (UCL70805F) that targets a protein called CD70 found on kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma who have tried standard treatments that are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced clear cell kidney cancer that has stopped responding to or you cannot tolerate standard treatments.
- You must have at least one tumor that can be measured on scans and a stored tumor sample that shows high levels of the CD70 protein.
- You need to be in generally good health (able to do daily activities without major help) and have adequate organ function.
- You cannot be pregnant, must avoid pregnancy during the trial, and must not have certain active infections (like hepatitis B, hepatitis C, HIV, or syphilis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
This trial tests a new type of immune cell therapy (CAR NK cells) that targets a protein called CD70 on kidney cancer cells. It's for people with advanced clear cell kidney cancer that hasn't responded to standard treatments.
This study tests a new cell-based treatment designed to target kidney cancer cells that have a protein called CD70. The treatment involves collecting your immune cells, modifying them in the lab, and infusing them back to fight the cancer. It's for patients with advanced kidney cancer who have already tried at least one standard immunotherapy.
This trial tests a new treatment using a patient's own immune cells, called CAR-NKT cells, which are designed to target and attack kidney cancer cells that have a specific marker called CD70. It may be an option for people whose clear cell kidney cancer has come back or spread after at least one prior treatment.
This study tests a new type of CAR-T cell therapy that targets a specific protein (CD70) on kidney cancer cells. It is for people with advanced kidney cancer who have already tried other treatments and have no standard options left.
This trial tests a new type of cell therapy (CAR-NK cells) designed to target kidney cancer that has spread or cannot be removed with surgery. The cells are engineered in the lab to recognize and attack cancer cells, and may help patients whose cancer has grown despite previous treatments.
Hear when a new CD70-positive Advanced Renal Clear Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.